Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.77 -2.5%	$2.42	$1.78 ▼ $10.14	$57.87M	0.7	252,573 shs	118,016 shs
HOOK HOOKIPA Pharma	$1.14	$1.39	$0.72 ▼ $6.68	$13.90M	0.89	82,013 shs	82,881 shs
HOWL Werewolf Therapeutics	$1.41 +0.7%	$1.18	$0.60 ▼ $4.18	$63.27M	0.62	441,704 shs	400,729 shs
PDSB PDS Biotechnology	$1.15 -4.2%	$1.45	$0.85 ▼ $4.32	$52.57M	1.21	475,618 shs	289,131 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+2.90%	+4.41%	+22.41%	-3.07%	-67.65%
HOOK HOOKIPA Pharma	0.00%	-7.32%	-12.98%	+47.42%	-82.43%
HOWL Werewolf Therapeutics	+3.70%	+29.63%	+15.70%	+52.34%	-51.39%
PDSB PDS Biotechnology	-0.83%	-7.69%	-25.93%	+11.11%	-70.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.4166 of 5 stars	3.4	4.0	4.8	1.6	2.5	0.6
HOOK HOOKIPA Pharma	3.0986 of 5 stars	3.2	5.0	0.0	2.7	1.7	0.6
HOWL Werewolf Therapeutics	3.8262 of 5 stars	3.5	5.0	0.0	1.6	5.0	0.6
PDSB PDS Biotechnology	1.1786 of 5 stars	3.7	1.0	0.0	1.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	771.79% Upside
HOOK HOOKIPA Pharma	2.33	Hold	$4.50	294.74% Upside
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	486.85% Upside
PDSB PDS Biotechnology	3.33	Buy	$9.00	679.22% Upside

Current Analyst Ratings Breakdown

Latest HOOK, HOWL, ADVM, and PDSB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/11/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/9/2025	HOWL Werewolf Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $6.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	57.03	N/A	N/A	$3.40 per share	0.80
HOOK HOOKIPA Pharma	$43.95M	0.32	N/A	N/A	$4.25 per share	0.27
HOWL Werewolf Therapeutics	$1.88M	33.89	N/A	N/A	$1.65 per share	0.86
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.51 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
HOOK HOOKIPA Pharma	-$43.50M	-$5.85	N/A	N/A	N/A	-785.66%	-120.09%	-77.14%	8/6/2025 (Estimated)
HOWL Werewolf Therapeutics	-$70.51M	-$1.67	N/A	N/A	N/A	N/A	-89.37%	-54.87%	8/14/2025 (Estimated)
PDSB PDS Biotechnology	-$37.61M	-$0.94	N/A	N/A	N/A	N/A	-150.59%	-69.15%	8/12/2025 (Estimated)

Latest HOOK, HOWL, ADVM, and PDSB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HOOK HOOKIPA Pharma	-$0.64	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	HOWL Werewolf Therapeutics	-$0.50	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	PDSB PDS Biotechnology	-$0.24	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	HOOK HOOKIPA Pharma	-$0.61	-$1.23	-$0.62	-$1.23	$3.38 million	N/A
5/14/2025	Q1 2025	PDSB PDS Biotechnology	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
5/8/2025	Q1 2025	HOWL Werewolf Therapeutics	-$0.44	-$0.40	+$0.04	-$0.40	$0.30 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
HOOK HOOKIPA Pharma	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
HOOK HOOKIPA Pharma	N/A	3.61	3.61
HOWL Werewolf Therapeutics	0.46	8.09	8.09
PDSB PDS Biotechnology	0.29	2.33	2.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
HOOK HOOKIPA Pharma	63.88%
HOWL Werewolf Therapeutics	64.84%
PDSB PDS Biotechnology	26.84%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
HOOK HOOKIPA Pharma	3.30%
HOWL Werewolf Therapeutics	23.60%
PDSB PDS Biotechnology	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
HOOK HOOKIPA Pharma	160	12.19 million	11.79 million	Optionable
HOWL Werewolf Therapeutics	40	44.87 million	34.28 million	Optionable
PDSB PDS Biotechnology	20	45.71 million	41.51 million	Optionable

HOOK, HOWL, ADVM, and PDSB Headlines

Recent News About These Companies

PDS wasn’t a bad deal, few greedy individuals cannibalised it with self-serving interests – John Jinapor

July 16 at 11:29 PM | modernghana.comM

PDS deal was not bad but greedy people decided to cannibalise the process - Jinapor

July 16 at 11:29 PM | ghanaweb.comG

Energy Minister blames ‘greedy individuals’ for undermining ‘otherwise good’ PDS deal

July 16 at 6:28 PM | myjoyonline.comM

PDS to pay final dividend of ₹1.70, ex-date due tomorrow; last day today to trade shares

July 16 at 5:14 AM | moneycontrol.com

The top headlines for PDS Health’s busy 2025 so far

July 12, 2025 | beckersdental.comB

PDS Biotechnology stock rises after trial meets criteria for expansion

July 10, 2025 | investing.com

PDS Biotechnology Shares Climb Following Trial Expansion Milestone

July 10, 2025 | msn.com

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

July 10, 2025 | globenewswire.com

ASIC consults on simplifying PDS guidance

July 10, 2025 | professionalplanner.com.auP

AP: over 11k kg of PDS rice seized in a private premise

July 10, 2025 | uniindia.comU

One arrested for smuggling PDS rice near Tiruchi

July 7, 2025 | thehindu.com

PDS Health adds practices in 5 states

July 3, 2025 | beckersdental.comB

3 booked for illegally transporting PDS food grains stock for sale in Thane

July 3, 2025 | theprint.inT

PDS arm inks pact to acquire 60% stake in GSC Link

July 3, 2025 | business-standard.comB

PDS Biotechnology (NASDAQ:PDSB) Given "Buy" Rating at HC Wainwright

July 1, 2025 | marketbeat.com

Two errant traders arrested; 79.3 quintals of PDS rice seized

June 25, 2025 | thehindu.com

PDS Health Raises Over $1.9 Million Through Smile Generation to Support charity: water's Clean Water Projects

June 25, 2025 | kxan.comK

PDS Biotechnology Corporation (PDSB) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

PDS Health ranked among most community-minded companies

June 13, 2025 | beckersdental.comB

Unpacking the PDS Phenomenon

June 11, 2025 | devdiscourse.comD

PDS rice will be distributed till June 30: Civil Supplies dept

June 11, 2025 | thehansindia.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOOK, HOWL, ADVM, and PDSB Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.77 -0.07 (-2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$2.76 0.00 (-0.18%)

As of 04:04 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

HOOKIPA Pharma NASDAQ:HOOK

$1.14 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 +0.08 (+7.28%)

As of 04:37 PM Eastern

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Werewolf Therapeutics NASDAQ:HOWL

$1.41 +0.01 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.40 0.00 (-0.35%)

As of 04:33 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

PDS Biotechnology NASDAQ:PDSB

$1.15 -0.05 (-4.17%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 +0.05 (+4.26%)

As of 04:25 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time